Meanwhile, in mid-June 2024, she began tirzepatide 2.5 mg weekly subcutaneously, titrated to 7.5 mg after 3 weeks, to facilitate weight reduction (baseline 85 kg, BMI 28) prescribed by her family doctor
Both medications commonly cause nausea, vomiting, and diarrhea during dose escalation, though tirzepatide's GIP pathway may increase gastrointestinal effects in some patients
Hunger may feel stronger and fullness may not last as long, which can influence eating patterns
That said, TRT can increase the risk of developing secondary polycythemia, a condition where the blood has an abnormally high concentration of red blood cells
165 : 3336 Bidzinska B, Petraglia F, Angioni S, Genazzani AD, Criscuolo M, Ficarra G et al